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ABSTRACT
Background: Aged garlic extract (AGE) and coenzyme Q10 (CoQ10) have been shown to affect multiple 
cardiovascular risk factors. The current study evaluates the effect of AGE combined with CoQ10 on 
inflammatory markers and progression of coronary atherosclerosis compared with placebo. Methods and 
Results: In this placebo-controlled, double-blind, randomized trial, 65 intermediate risk firefighters (age 
55 ± 6 years) were treated with a placebo capsule or a capsule containing AGE and CoQ10 (AGE+CoQ10, 
1200 and 120 mg, respectively) daily for 1 year. All participants underwent coronary artery calcium (CAC) 
scanning and C-reactive protein (CRP) at baseline and at 12 months. At 1 year, mean CAC progression 
was significantly lower in AGE+CoQ10 (32 ± 6 vs. 58 ± 8, P = 0.01) than placebo. Similarly, CRP were 
significantly decreased in AGE+CoQ10 compared with placebo (-0.12 ± 0.24 vs. 0.91 ± 0.56 mg/L, P < 
0.05). After adjustment for age, gender, conventional cardiac risk factors, and statin therapy, AGE+CoQ10 
was associated with 3.99 fold (95% 1.3–12.2, P = 0.01) lack of CAC progression compared with the placebo. 
Conclusion: AGE+CoQ10 are associated with beneficial effects on inflammatory markers and reduced 
progression of coronary atherosclerosis.
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multiple factors involved in the atherosclerosis process 
including IL-1, TNF-α, and TGF-β, and migration of 
smooth muscle cells into intima.[1] Aged garlic extract 
(AGE) has been shown to reduce the progression 
of coronary atherosclerosis, improve vascular 
function, and have favorable effect on oxidative 
biomarkers. [2,3] AGE has effects on coronary 
atherosclerosis by preventing smooth muscle cell 
transformation and proliferation, preventing entry 
of lipids into arterial wall and macrophages, and also 
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INTRODUCTION
Atherosclerosis is a complex phenomenon involving 
deposition of lipoproteins into the arterial intima, 
oxidative modification of lipids, recruitment of 
leukocytes into the lesion, uptake of oxidized lipids 
into macrophages to create foam cells, release of 
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Clinical Trials Registry Information: This trial has been 
registered with ClinicalTrials.gov. (ClinicalTrials.gov Identifier: 
NCT00860847)
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directly suppressing atherosclerosis.[4,5] AGE has been 
shown to have beneficial effects on arterial function 
by inhibiting endothelial cell damage, transforming 
smooth muscle cells, and inhibiting the damage of 
nitric oxide synthesis.[6,7] AGE helps to modulate 
cardiovascular risk factors by lowering blood pressure, 
inhibiting platelet aggregation and adhesion, lowering 
cholesterol, preventing low-density lipoproteins 
(LDL) oxidation and smoking-induced oxidative 
damage. [4,8-10] 
There is accumulating evidence that suggests the role 
of inflammation in atherosclerosis process. C-reactive 
protein (CRP) is a nonspecific marker of inflammation, 
measured by levels of highly sensitive CRP (hsCRP), 
which may be increased in many pathological processes. 
CRP is also a mild predictor of future cardiovascular 
events and is intermittently used for risk assessment of 
selected asymptomatic population.[11-13] 
Coenzyme Q10 (CoQ10) is present in all cellular 
membranes and acts as an electron carrier from 
complex I and complex II to complex III and the 
translocation of protons in the mitochondrial 
respiratory chain.[14] CoQ10 has been shown to 
have antioxidant properties by preventing oxidative 
modification of LDL, helping regeneration of 
α-tocopherol from the tocopheroxyl radical and as a 
scavenger for free radicals.[15-16] CoQ10 concentration 
has been shown to be lower in patients with coronary 
artery disease and the LDL/CoQ10 ratio has been 
shown to be a coronary risk factor.[17-19] 
Both AGE and CoQ10 may help modify multiple 
cardiovascular risk factors for coronary atherosclerosis 
disease. This randomized placebo-controlled, double-
blinded trial was designed to test the hypothesis that 
the combined formulation of AGE and CoQ10 will 
have beneficial effect on atherosclerosis by reducing 
the progression of atherosclerosis, measured by 
coronary artery calcium (CAC). Furthermore, the 
combined formulation will also have positive effect 
on inflammatory biomarker profiles.
MATERIALS AND METHODS
This placebo-controlled, double-blind randomized 
trial was designed to look at the combined effect 
of a commercially available AGE and CoQ10 
supplement (Kyolic 110, Wakunaga Nutritional 
Supplement, CA, USA) on coronary atherosclerosis 
plaque burden and inflammatory biomarkers. The 
firefighter participants were enrolled at Los Angeles 
Biomedical Research Institute at Harbor-UCLA 
Medical Center. The Investigational Review Board 
of Los Angeles Biomedical Research Institute at 
Harbor-UCLA Medical Center approved this research 
project. The authors of this manuscript have certified 
that they comply with the Principles of Ethical 
Publishing mentioned in the International Journal of 
Cardiology.[20] 
Study population
Sixty five firefighter participants who had CAC score 
>10 at baseline were included in the study. Subjects 
were required to be on stable concomitant medications 
for at least 12 weeks prior to randomization and 
agree to refrain from supplemental or significant 
dietary garlic or CoQ10. Subjects also signed written 
informed consent approved by the Institutional 
Review Board of Los Angeles Biomedical Research 
Institute. Exclusion criteria for the study included any 
known hypersensitivity to AGE or CoQ10 therapy, 
any unstable medical, psychiatric, or substance abuse 
disorder that may interfere with continuation in 
the study, weight ≥325 pounds, bleeding disorder, 
history of myocardial infarction, stroke or life-
threatening arrhythmia within prior 6 months, resting 
hypotension (systolic < 90 mmHg) or hypertension 
(resting blood pressure >170/110), heart failure 
NYHA class III or IV, history of malignancy within 
the last 5 years (other than skin cancer) or evidence 
of active cancer which would require concomitant 
cancer chemotherapy, serum creatinine >1.4 mg/dl, 
triglycerides > 400 at baseline visit, diabetic subjects 
with HbA1C >12%, drug or alcohol abuse or current 
intake of more than 14 standard drinks per week and 
current enrollment in another placebo-controlled 
trial. Conditions interfering with accurate assessment 
of coronary calcification (metal clips, bypass patients, 
intracoronary stents) and drug absorption (partial ileal 
bypass or malabsorption syndrome) were exclusion 
criteria. Current use of anticoagulants (except for 
antiplatelet agents), chronic renal or liver failure, and 
hematological or biochemical values at baseline visit 
outside the reference ranges considered as clinically 
significant in the opinion on the investigator were 
also part of exclusion criteria.
The participants were assigned to AGE plus CoQ10 
or placebo in a double-blinded manner, using 
numbered containers assigned to a computer-generated 
randomization chart by the nurse coordinator. All 
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participants, personnel administering the intervention 
and the physicians involved in the study were blinded 
to the randomization. A capsule of placebo or 
commercially available AGE (1200 mg) plus CoQ10 
(120 mg) was given daily for the duration of 1 year. All 
participants were educated on a low-cholesterol diet 
and instructed to avoid any direct form of garlic and 
CoQ10 supplementation. All participants underwent 
CAC and CRP assessment at baseline and 12 months.
After randomization, participants were followed up at 
3, 6, 9, and 12 months to assess their compliance with 
medication, blood pressure, and weight measurement.
Coronary artery calcium measurement
CAS studies were performed with 64-multidetector 
computed tomography scanner (Light Speed VCT 
scanner, GE Healthcare, Milwaukee, Wisconsin). 
Electrocardiographic triggering was performed at 75% 
of the R-R interval. The coronary arteries were imaged 
with at least 48 consecutive nonenhanced images at 2.5 
mm slice thickness. Subjects underwent similar repeat 
examination at the end of the study protocol.
CAC score measurements were performed on 
noncontrast studies by an experienced reader blinded 
to the patient’s clinical information. CAC was defined 
as a plaque of at least three contiguous pixels (area 1.02 
mm2) with a density of >130 Hounsfield units. The 
lesion score was calculated by multiplying the lesion area 
by a density factor derived from the maximal Hounsfield 
unit within this area, as described by Agatston et al.[21] 
The density factor were derived in the following manner: 
1 for lesions with peak attenuation of 130–199, 2 for 
lesions with peak attenuation of 200–299, 3 for lesions 
with peak attenuation of 300–399, and 4 for lesions 
with peak attenuation of >400. Total calcium score 
was determined by summing individual lesion scores 
from each of the four main coronary arteries (left 
main coronary, left anterior descending coronary, left 
circumflex coronary, and right coronary arteries).
Statistical analysis
All continuous data are presented as a mean value ± 
SD, and all categorical data are reported as a percentages 
or absolute numbers. The power analysis was based 
on our previously published studies evaluating the 
effect of garlic and supplements on coronary 
atherosclerosis.[2,3] Student’s t tests and chi-square 
tests were used to assess differences between groups. 
Comparisons of all parameters between the active 
therapy and placebo were made with the Student’s t 
test. Trends of all parameters during follow-up periods 
were examined using matched pair t tests. The primary 
end point was the effect of AGE+CoQ10 on absolute 
change in CAC from baseline and secondary end points 
included the effect of AGE+CoQ10 on inflammatory 
biomarkers. The associations between changes in the 
two treatment groups over 1 year between groups 
(active therapy and placebo) for risk factors, including 
lipid profile, CAC, and CRP were analyzed by logistic 
regression analyses. These analyses were adjusted for 
demographics, age, gender, and traditional cardiac risk 
factors. Odds ratios were calculated for median annual 
change of lack of CAC progression, decrease in CRP, 
and decrease in BMI.
RESULTS
Demographic and baseline clinical information of 
Table 1: Baseline demographic and clinical 
characteristics of study participants and absolute 
change at 1 year follow-up
Variables AGE +CoQ10 Placebo P value
Baseline




CAC 169 ± 29 211 ± 49 0.6
hsCRP 1.9 ± 2.1 1.9 ± 2.4 0.9
BMI 28 ± 3 29 ± 4 0.5
Absolute change at 1-year follow-up
CAC 32 ± 6 58 ± 8 0.01
hsCRP -0.12 ± 0.24 0.91 ± 0.56 0.01
BMI -0.47 ± 0.82 0.28 ± 1.27 0.03
BUN = Blood urea nitrogen; CVD = Cardiovascular disease; FHX = Family history 
of cardiac disease; HDL = High-density lipoprotein; HTN = Hypertension; LDL = 
Low-density lipoprotein; n = Number.
Figure 1: CONSORT statement (Consolidated Standards of Reporting 
Trials) flow chart
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the AGE + CoQ10 and placebo group participants 
are given in Table 1. The CONSORT (Consolidated 
Standards of Reporting Trials) statement is given in 
Figure 1. These participants were enrolled during 
2009–2010 period. Initially, 65 participants were 
enrolled in the study. Five participants withdrew 
their consent during the course of the trial. Two 
participants were removed from the trial due to 
diagnosis of medical conditions that were exclusion 
criteria for the study (bleeding disorder and cancer). 
Eight participants dropped out due to relocation or 
unable to follow up with the scheduled visits. Finally, 
24 and 26 participants from AGE + CoQ10 group and 
the placebo group were analyzed in the final analysis, 
respectively. Safety information was collected as part 
of the trial and none of the participants had significant 
adverse reaction mandating removal from the study.
There were no significant differences between placebo 
and AGE+CoQ10 groups at baseline based on 
conventional cardiac risk factors. The mean CAC 
scores (169 ± 29 vs. 211±49, P > 0.05) and CRP (1.9 ± 
2.1, 1.9 ± 2.4, P > 0.05) at baseline for AGE+CoQ10 
and placebo groups were not significantly different. 
The absolute change in CAC at 1 year follow-up in 
AGE+CoQ10 and placebo groups was 32 ± 6 and 58 
± 8 (P = 0.01), respectively. At 1 year, mean CAC 
progression was significantly lower in AGE+CoQ10 
(32 ± 6 vs. 58 ± 8, P = 0.01) than placebo.
Similarly, CRP were significantly decreased in 
AGE+CoQ10 compared with placebo (-0.12 ± 0.24 
vs. 0.91 ± 0.56 mg/L, P < 0.05).
Table 2 shows the results of logistic regression 
analysis looking at the odds of various parameters 
in AGE+CoQ10 group compared with placebo 
taken as reference group. The results detail median 
annual changes in these parameters and the results 
were adjusted for age, gender, diabetes, hypertension, 
hyperlipidemia, family history of CAD, smoking 
status, and statin therapy. After adjustment for age, 
gender, diabetes, hypertension, hyperlipidemia, family 
history of CAD, smoking status, and statin therapy, 
AGE+CoQ10 was associated with 3.99 odds (95% 
1.3– 12.2, P = 0.01) for lack of CAC progression. 
DISCUSSION
This study demonstrates that AGE+CoQ10 reduce the 
progression of CAC and has a marked beneficial effect 
on inflammation over a 1 year follow-up period. These 
data are consistent with prior studies documenting 
reduced progression of CAC by AGE alone[2] and 
AGE supplemented with B vitamins, folic acid, and 
L-arginine.[3,22] 
CAC not only provides information regarding 
cardiovascular risk but it can also be used to track 
progression of atherosclerosis over time.[13, 23-25] In the 
current study, the annual progression rate for CAC in 
the placebo group was significantly higher compared 
with AGE + CoQ10 group (58 ± 8 vs. 32 ± 6, P = 
0.01). In our prior study of AGE supplemented with B 
vitamins, folic acid, and L-arginine where all patients 
were treated with statins, a procession rate of 6.8% 
was noted compared to 26.5% in the placebo arm.[3] 
In the current study, only 24.24% of patients in the 
AGE+CoQ10 were taking statins compared with 
31.25% of patients in the placebo group. Despite of the 
low use of statins in current study, the rate of CAC 
progression was significantly less in AGE+CoQ10 
compared to placebo. AGE+CoQ10 worked to slow 
CAC progression in both participants taking statins 
and those not taking statins, thus the benefit of this 
supplement is clearly independent, but incremental to, 
statin use.  In addition to lower rate of progression of 
CAC, participants in AGE+CoQ10 group had lower 
CRP levels compared with placebo group.
CoQ10 is a coenzyme present in the inner mitochondrial 
membranes enzyme complexes, as a component of 
the mitochondrial respiratory chain, involved in 
oxidative phosphorylation.[14] CoQ10 may be helpful 
in atherosclerosis prevention and progression by 
acting as an antioxidant and helping lowering blood 
pressure.[15-16,26] Studies have shown significantly lower 
concentration of CoQ10 in patients with coronary artery 
disease compared with control patients. These studies 
also showed ratio of CoQ10 and LDL to be lower in 
patients with coronary artery disease compared with 
control patients.[17-18] Singh et al.[27] studied the effect of 
oral CoQ10 supplementation after acute myocardial 
Table 2: Results of logistic regression analysis
Model Placebo Pl AGE +CoQ10
Lack of CAC 
Progression*
1.0 (Reference) 3.99 (95% 1.3-12.2), 
P = 0.01
Decrease in hsCRP* 1.0 (Reference) 7.67 (95% 2.7-21.9), 
P = 0.001
Decrease in BMI* 1.0 (Reference) 1.8 (95% 1.1-5.8), 
P = 0.01
Logistic Regression Analysis, Adjusted for age, gender, conventional risk factors and 
statin therapy, *Median annual change, CAC < 25AJ vs. CAC ³25, CRP < 0 vs. CRP 
³0, BMI < 0 vs. BMI ³0
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infarction. After 1 year follow-up, total cardiac events 
(24.6 vs. 45.0, P < 0.02) including nonfatal infarctions and 
cardiac deaths were significantly reduced in the treatment 
group compared to control group. Wittig et al.[28] studied 
the antiatherogenic effects of CoQ10 supplementation 
in apolipoprotein E gene knockout mice fed on a high 
fat diet. CoQ10 supplementation significantly reduced 
aortic atherosclerotic lesion size and markers of lipid 
peroxidation in Apolipoprotein E gene knockout mice 
compared to controls.
Limitations
This was a relatively small randomized trial and larger 
trials are needed to confirm the findings. Furthermore, this 
study was too small to evaluate for reduction of outcomes 
with this formulation. Since the formulation given to 
participants on active therapy contained AGE and CoQ10 
in a single capsule, we cannot assess the effects on AGE 
and CoQ10 on the CAC progression separately. CAC 
progression was defined by the absolute change in CAC 
scores that may be affected by the interscan variability. 
We included only firefighters in this study. Firefighters 
are usually healthy group of population, but under 
more stress, and studies have demonstrated increased 
cardiovascular events in this population.[29]
CONCLUSION
This is the first study to our knowledge evaluating the 
effect of combination of AGE and CoQ10 on coronary 
atherosclerosis and inflammatory biomarkers. 
Participants taking AGE and CoQ10 combination 
were found to have significant improvements in CAC 
and CRP, suggesting improvement in cardiovascular 
health.  These findings were incremental to, and 
independent of, statin use, which also have beneficial 
effects on both atherosclerosis and CRP. The current 
study and the prior two studies documenting the effect 
of AGE on CAC and inflammatory biomarkers sets 
the stage for an outcomes based study to assess whether 
this approach may reduce CVD events.
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